# ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia

> **NCT07420959** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 38 (estimated)

## Conditions studied

- Recurrent Waldenstrom Macroglobulinemia
- Refractory Waldenstrom Macroglobulinemia

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Etentamig
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT07420959
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-25
- **Primary completion:** 2036-03-25
- **Final completion:** 2038-03-25
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07420959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07420959, "ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07420959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*